A Phase 3 Randomized, Double-Blind Study Assessing The Efficacy And Safety Of PF-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate

Trial Profile

A Phase 3 Randomized, Double-Blind Study Assessing The Efficacy And Safety Of PF-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLECTIONS B537-02
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Dec 2017 According to a Pfizer media release, United States Food and Drug Administration has approved IXIFI (PF-06438179, infliximab-qbtx), as a biosimilar to Remicade (infliximab) for the treatment of patients with rheumatoid arthritis. data from this trial was included in the Biologics License Application.
    • 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 01 Sep 2017 This trial has been completed in Germany (end date: 2017-06-01)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top